ArticleCell2021
Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States.
Article in Cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 256 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
256 citing papers in PubMed.
- Multi-antigen coronavirus vaccine induces potent and durable cross-protection against multiple SARS-CoV-2 variants.NPJ vaccines · 2026Article
- SARS-CoV-2 Delta variant re-emerges in US farmed mink and free-ranging white-tailed deer in 2022-2023.Nature communications · 2026Article
- DNA methylation profiles at hospital admission are associated with subsequent severe COVID-19 outcomes.Clinical epigenetics · 2026Article
- Quantifying the spatiotemporal dynamics of the first two epidemic waves of SARS-CoV-2 infections in the United States.PLoS computational biology · 2026Article
- Slowdown of synonymous substitution rate preceding the emergence of multiple SARS-CoV-2 variants.Virus evolution · 2026Article
- Inferring epidemiological parameters under an infectious phylogeography model with visitor dynamics.medRxiv : the preprint server for health sciences · 2025Article
- Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Cross-reactive sarbecovirus antibodies induced by mosaic RBD-nanoparticles.bioRxiv : the preprint server for biology · 2025Article
- JN.1 variants circulating in Italy from October 2023 to April 2024: genetic diversity and immune recognition.BMC infectious diseases · 2025Article
- Article
- Inferring effects of mutations on SARS-CoV-2 transmission from genomic surveillance data.Nature communications · 2025Article
- Phylogenetic insights into the early spread of the SARS-CoV-2 Alpha variant across Europe.Virus evolution · 2025Article
- Lower cancer incidence three years after COVID-19 infection in a large veteran population.PloS one · 2025Article
- Dynamics of spike-specific neutralizing antibodies across five-year emerging SARS-CoV-2 variants of concern reveal conserved epitopes that protect against severe COVID-19.Frontiers in immunology · 2025Article
- Advancements in Structural Basis of Covalent Inhibitors Targeting SARS-CoV-2 Essential Proteins.Current medicinal chemistry · 2025Review
- Aromatase, testosterone, TMPRSS2: determinants of COVID-19 severity.Biology of sex differences · 2024Article
- Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals.Cell · 2024Article
- Dynamics of Spike-Specific Neutralizing Antibodies Across Five-Year Emerging SARS-CoV-2 Variants of Concern Reveal Conserved Epitopes that Protect Against Severe COVID-19.bioRxiv : the preprint server for biology · 2024Article
- Low-frequency CD8NPJ vaccines · 2024Article
- Clinical characterisation, treatment outcomes, and case fatality risk of patients with different SARS-CoV-2 variants in Bangladesh.Journal of global health · 2024Observational
196 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Update of
Authors and funding
54 authors.
Funding
Abstract
The highly transmissible B.1.1.7 variant of SARS-CoV-2, first identified in the United Kingdom, has gained a foothold across the world. Using S gene target failure (SGTF) and SARS-CoV-2 genomic sequencing, we investigated the prevalence and dynamics of this variant in the United States (US), tracking it back to its early emergence. We found that, while the fraction of B.1.1.7 varied by state, the variant increased at a logistic rate with a roughly weekly doubling rate and an increased transmission of 40%-50%. We revealed several independent introductions of B.1.1.7 into the US as early as late November 2020, with community transmission spreading it to most states within months. We show that the US is on a similar trajectory as other countries where B.1.1.7 became dominant, requiring immediate and decisive action to minimize COVID-19 morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.